Table 1 asas
Author, year | Location | Participants | Intervention Treatment | Control Treatment | Outcomes | Intervention | Control |
|---|---|---|---|---|---|---|---|
Balaskas, 2012 | Switzerland | N = 19 Intervention = 10 Control = 9 | Azithromycin + prednisone Administration route: oral | PYR/SDZ + folinic acid + prednisone Administration route: oral | Changes in VA Number of recurrences Improvement in VA Ocular inflammation Retinal lesion Size | NR NR NR NR NR | NR NR NR NR NR |
Adverse drug reactions (minor) | NR | 9 (100%) | |||||
Baharivand, 2013 | Iran | N = 66 Intervention = 32 Control = 34 | Clindamycin + dexamethasone Administration route: intravitreal | PYR/SDZ + folinic acid + prednisone Administration route: oral | Changes in VA | 0.38 ± 0,35 logMAR | 0.35 ± 0,29 logMAR |
Number of recurrences | 4 (12.5%) | 5 (14.7%) | |||||
Improvement in VA (gaining > = 2 Snellen lines) | 27/32 | 28/34 | |||||
Ocular inflammation (grade 0/trace) | 28 (87.5%) | 28 (82.4%) | |||||
Retinal lesion size improvement | 21 (65.6%) | 23 (67.6%) | |||||
Adverse drug reactions (major) | 0 | 1 (2.9%) | |||||
Bosch-Driessen, 2002 | Netherlands | N = 46 Intervention = 24 Control = 22 | PYR + Azithromycin + folinic acid + prednisone Administration route: oral | PYR/SDZ + folinic acid + prednisone Administration route: oral | Changes in VA | NR | NR |
Number of recurrences (at least one year follow up) | 5 /15 (33%) | 5 / 9 (56%) | |||||
Improvement in VA (> = 0.5 logMAR units at 3 months) | 5 /24 (21%) | 5/18 (28%) | |||||
Ocular inflammation (No inflammatory cells from vitreous within 4 w) | 14 /20 (70%) | 10/14 (71%) | |||||
Retinal lesion size improvement (decrease more than 0,5 optic disk diameter in 3 months) | 9/ 22 (41%) | 7 /17 (41%) | |||||
Adverse drug reactions (all) | 8/ 24 (33%) | 14 /22 (64%) | |||||
Colin, 1989 | Not exactly reported | N = 29 Intervention = 14 Control = 15 | Clindamycin Administration route: subconjunctival injections + oral prednisolone | PYR/SDZ + Prednisolone Administration route: oral Folinic acid Administration route: Intramuscular | Changes in VA Ocular inflammation Improvement in VA Retinal lesion Size | NR NR NR NR | NR NR NR NR |
Number of recurrences | 21% | 36% | |||||
Adverse drug reactions (all) | 1 | 1 | |||||
Ghavidel, 2017 | Iran | N = 72 Intervention = 36 Control = 36 | Azithromycin + prednisolone Administration route: oral | PYR/SDZ + prednisolone Administration route: oral | Changes in VA Ocular inflammation | 0.35 logMAR (20/44 Snellen acuity) NR | 0.39 logMAR (20/49 Snellen acuity) NR |
Improvement in VA | NR | NR | |||||
Number of recurrences (during 24 months after treatment) | 18 (50%) | 4 (11,1%) | |||||
Retinal lesion size (reduction during treatment) | 354.86 µm | 638.89 µm | |||||
Adverse drug reactions (all) | 4 (12.5%) | 20 (55.5%) | |||||
Kartasasmita, 2017 | Indonesia | N = 28 Intervention = 14 Control = 14 | TMP/SMX + Clindamycin + methylprednisolone Administration route: oral | PYR/SDZ + methylprednisolone + folic acid Administration route: oral | Changes in VA Number of recurrences Improvement in VA Ocular inflammation Adverse drug reactions | NR NR NR NR NR | NR NR NR NR NR |
Retinal lesion size (percentage of lesion area reduction in the third w) | 57.50% | 52.5% | |||||
Lashay, 2017 | Iran | N = 27 Intervention = 14 Control = 13 | Azithromycin + prednisone Administration route: oral | TMP/SMX + Prednisone Administration route: oral | Changes in VA | 0.24 ± 0.04 logMAR | 0.30 ± 0.01 logMAR |
Number of recurrences Improvement in VA | NR 10/14 | NR 10/13 | |||||
Ocular inflammation (vitreous inflammatory cells clearance) | 7 (50%) | 10 (77%) | |||||
Retinal lesion size (reduction) | 24.2% ± 6,5% | 36.6% ± 4,6% | |||||
Adverse drug reactions (mild) | 4 (28.5%) | 3 (23%) | |||||
Ortega, 2000 | Mexico | N = 46 Intervention G1 = 13 Intervention G2 = 22 Intervention G3 = 11 | G1 TMP/SMX + PYR + prednisone + folinic acid G2 TMP/SMX + Clindamycin + prednisone Administration route: oral G3 TMP/SMX + PYR + Clindamycin + prednisone + folinic acid Administration route: oral | - | Changes in VA Improvement in VA Ocular inflammation Retinal lesion size | NR NR NR NR | - - - - |
Number of relapses | G1 1 (7.6%) G2 5 (31.2%) G3 4 (36.3%) | ||||||
Adverse drug reactions (called “Complications from treatment” and apparently mild) | G1 1 (7.6%) G2 4 (18.1%) G3 0 (0%) | - | |||||
Soheilian, 2005 | Iran | N = 59 Intervention = 30 Control = 29 | TMP/SMX + oral prednisolone Administration route: oral | PYR/SDZ + folinic acid + prednisolone Administration route: oral | Improvement in VA | NR | NR |
Changes in VA (increase) | 0,52 logMAR | 0,56 logMAR | |||||
Number of recurrences | 3 (10%) | 3 (10,3%) | |||||
Ocular inflammation (Reduction of vitreous inflammatory cells (0–trace cells) 6 w after treatment) | 17 (56,7%) | 20 (69%) | |||||
Retinal lesion size (mean reduction 6 w after treatment) | 59% | 61% | |||||
Adverse drug reactions | 1a/31 (2,8%) | 1a/30 (2,9%) | |||||
Soheilian, 2011 | Iran | N = 68 Intervention = 34 Control = 34 | Clindamycin + dexamethasone Administration route: intravitreal | PYR + SDZ + folinic acid + prednisolone Administration route: oral | Improvement in VA | NR | NR |
Changes in VA (increase) | 0,44 ± 0,24 logMAR | 0,29 ± 0,19 logMAR | |||||
Number of recurrences (eyes) | 2 | 2 | |||||
Ocular inflammation (trace or no vitreous cells) | 15 (51,7%) | 15 (55,5%) | |||||
Retinal lesion size (calculated in pixels using MATLAB environment) | 116,994 +—143,997 Pixels | 89,606 +—651,553 pixels | |||||
Adverse drug reactions (all) | 4/34 | 2a/36 |